+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 12Years - 18Years
All Genders
ID07762443

Phase I Trial Evaluating the Pharmacokinetics and Safety of VC005 Tablets in Adolescents with Severe Alopecia Areata

Led by Jiangsu vcare pharmaceutical technology co., LTD · Updated on 2026-10-20

24

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This trial investigates VC005 tablets in adolescents aged 12 to under 18 years with severe alopecia areata AA. It is a multicenter, open-label, non-randomized Phase I study designed to evaluate how the drug behaves in the body pharmacokinetics, its safety, and early signs of how it might work for this condition. Participants receive VC005 tablets at two different dose levels over a 24-week period. The study explores the drugs exposure in the blood by measuring key pharmacokinetic parameters on Day 1 and Day 28. This dose-finding study helps identify safe and appropriate dosing in this young population. During the study, participants are closely monitored with assessments including blood tests to measure drug levels and safety evaluations. Researchers measure outcomes such as the amount of drug in the bloodstream over time and peak concentration levels. The total duration of treatment is 24 weeks, with ongoing safety and efficacy observations throughout this period.

CONDITIONS

Brief Title

A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata

Research Team

X

xiaojuan lai

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here